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SERIAL FECAL ASCA MEASUREMENTS IN THE EVALUATION OF  
CHILDREN WITH CROHN DISEASE 
 
RACHEL P. MOJDEHBAKHSH 
ABSTRACT 
Background: Pediatric patients with Inflammatory Bowel Disease (IBD) undergo costly 
and invasive investigations to diagnose and treat their chronic disease. To that end, it is 
important for researchers and physicians to continue to work to find novel tools to 
improve diagnosis and treatment processes. One of the main challenges is differentiating 
between the two main forms of IBD, Crohn disease (CD) and ulcerative colitis (UC). 
Physicians currently rely on a combination of endoscopic evaluations, mucosal biopsies, 
radiology studies, and biochemical testing to assess for the presence and extent of 
inflammation in the gastrointestinal (GI) tract. Serologic biomarkers can be useful to 
some extent, but changes in these markers do not typically reflect disease specific to the 
GI tract, or the state of inflammation related to a patient’s IBD. In contrast, fecal 
biomarkers have the unique potential to provide specific information about inflammation 
in the GI tract. While serum antibody levels have been well studied for use in the 
diagnosis of patients with IBD, fecal antibody levels and anti-saccharomyces cerevisiae 
antibody (ASCA) in particular, have not been extensively evaluated. In this study, we 
will assess the dynamic range of fecal ASCA levels in acute and convalescent fecal 
samples collected from children and adolescents with CD and UC.  
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Methods: We recruited pediatric patients from inpatient and ambulatory settings at the 
Gastroenterology Program at Boston Children’s Hospital. Patients had a diagnosis of 
either CD or UC. We collected baseline stool samples during a point of active disease, 
and follow-up samples three to six months later during a point of inactive disease. 
Samples were analyzed for fecal ASCA as well as lactoferrin (FLA), another marker of 
inflammation that can be measured in the stool.  
 
Results: In patients with CD, fecal ASCA levels were significantly higher during active 
disease than during inactive disease. Additionally, fecal ASCA levels were higher in 
patients with CD than in patients with UC, regardless of disease activity. When compared 
to FLA, ASCA was shown to differentiate between CD and UC, with greater changes in 
the level of fecal ASCA (active – inactive) correlating with a diagnosis of CD. In patients 
with CD, FLA levels were significantly higher in the context of active disease than in 
inactive disease. However, FLA did not differentiate between CD and UC.  
 
Conclusions: Our results suggest that fecal ASCA may be a new marker of inflammation 
in the GI tract. Unlike FLA, changes in fecal ASCA levels appear more dynamic in 
patients with CD. Future studies are required to further demonstrate both how changes in 
fecal ASCA may help physicians distinguish between different forms of IBD as well as 
how measurement of fecal ASCA may help assess disease activity and response to 
therapy in patients with CD.  
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INTRODUCTION 
Inflammatory Bowel Disease (IBD) is characterized by idiopathic and chronic 
inflammation of the gastrointestinal (GI) tract (“Inflammatory bowel disease,” 2015). 
IBD encompasses two main diagnoses, Crohn disease (CD) and ulcerative colitis (UC), 
and the two are distinguished by the location and extent of inflammation (“Crohn’s 
Disease,” 2014; “Ulcerative Colitis,” 2014). IBD affects over one million Americans and 
at least 20% of those are diagnosed in childhood (Hendrickson, Gokhale, & Cho, 2002; 
Rufo & Bousvaros, 2006). Studying early onset disease in children may provide 
researchers with a unique opportunity to obtain new insights into the pathogenesis of IBD 
(Sauer & Kugathasan, 2010). Presently, the process for diagnosing IBD is both invasive 
and costly and relies on endoscopic assessment and the interpretation of mucosal 
biopsies. Research is underway to find novel and less invasive approaches to both stratify 
which patients, and especially which children, are most likely to benefit from more 
definitive testing and to assess an individual patient’s response to therapy. One way 
researchers are working to solve this problem is with the use of fecal biomarkers. These 
proteins can be measured in the stool of patients with IBD, and previous studies have 
demonstrated that they may be useful in assessing the presence of inflammation in the GI 
tract (Assche, 2011).  
 
Biomarkers  
 Biomarkers are readily obtained objective indicators of relevant biological 
outcomes occurring in the body. Ideally, changes in levels of biomarkers correlate with a 
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clinically relevant endpoint. A biomarker can be anything from blood pressure to an 
antibody level. The use of biomarkers becomes necessary when measuring an outcome 
directly is too invasive, costly, or cannot be sustained. Changes in the level of a particular 
biomarker may predate changes in clinical course. As such, the use of biomarkers may 
afford clinicians the opportunity to provide proactive changes in therapy, thereby 
reducing the likelihood of the development of clinically significant disease. Therefore, 
biomarkers can be used to stratify clinical outcome or response to a particular therapy 
(Strimbu & Tavel, 2011).  
 Some examples of current biomarkers in widespread use include serum 
cholesterol for risk of heart disease and human chorionic gonadotropin (hCG) for 
detection of a pregnancy in a urine test. To clinicians, biomarkers are useful for making a 
diagnosis, assessing response to therapy, predicting relapse, and assessing disease state. 
In addition, biomarker development is of tremendous interest to the pharmaceutical 
industry in that robust biomarkers can be employed to reduce both the cost of clinical 
drug trials and potential adverse effects. Biomarkers can also elucidate disease processes 
and indicate potential targets for new interventions.  
 Biomarkers, therefore, can have an impact upon the entire spectrum of healthcare, 
from the creation of drugs to the long term care of patients. However, biomarkers must be 
validated to demonstrate that they accurately reflect underlying processes and provide 
valid and relevant information about a condition if they are to dictate subsequent actions. 
In addition, it is important to remember that although biomarkers may serve to reflect 
changes in biological processes, they are not the actual outcome in question. 
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Consequently, physicians and researchers must be aware of this limitation when drawing 
conclusions about changes in therapy and reporting clinical prognosis (Strimbu & Tavel, 
2011).  
 
Clinical Presentation of Crohn Disease and Ulcerative Colitis 
Patients presenting with CD and UC can look very similar clinically. Ultimately, 
physicians must rely on the location and histology of the inflamed tissue in the context of 
patients’ symptoms to make a definitive diagnosis. CD can affect any portion of the GI 
tract and the involved segments can be discontinuous. In contrast, the inflammation 
observed in patients with UC is confined to the colon and is continuous in nature. 
Additionally, the inflammation in patients with CD can be transmural, affecting multiple 
layers of the GI tract, whereas the inflammation seen in UC is generally limited to the 
superficial mucosa lining the colon (Hendrickson et al., 2002; Abraham & Cho, 2009). 
Due to the invasive nature of inflammation in CD, patients are at risk for a number of 
long-term complications including strictures, obstructions, and fistulae or aberrant 
connections of the intestines to other portions of the GI tract or intestinal viscera 
(Abraham & Cho, 2009). Pediatric patients with CD typically present with disease 
limited to the ileocolonic or colonic regions. The majority of pediatric patients with UC 
are found to have pancolitis, which affects the entire colon, as opposed to primarily left-
sided colitis that is more frequently found in adults with UC (Sauer & Kugathasan, 
2010).  
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Patients with CD and UC can present with both intestinal and extraintestinal 
symptoms. The most common clinical symptoms are diarrhea, abdominal pain, and loss 
of appetite. The physical appearance of stool is one way to begin to differentiate between 
CD and UC. Patients with UC typically present with visible blood and mucus in their 
stool, which is not always the case in patients with CD (Hendrickson et al., 2002; 
Bousvaros et al., 2007). In contrast, patients with CD more often present with more 
indolent symptoms including weight loss and growth delay due to chronic inflammation 
in the small bowel, leading to intestinal dysfunction and malabsorption (Hendrickson et 
al., 2002). 
 
Epidemiology of Inflammatory Bowel Disease 
The incidence of IBD is highest in North America and Europe. However, IBD is 
becoming increasingly common in developing regions of the world including China, 
South Korea, India, Lebanon, Iran, Thailand, French West Indies, and North Africa 
(Ponder & Long, 2013). This increase in prevalence likely correlates with an 
intermingling of genetics and the “Westernization” of these countries with respect to diet 
and lifestyle, and thus provides some evidence for the role of environmental risks in the 
development of IBD (Loftus, 2004; Benchimol et al., 2011; Ponder & Long, 2013). 
Interestingly, emigrants moving from a geographic area with lower incidence to one with 
higher incidence ultimately are at greater risk for the development of IBD (Benchimol et 
al., 2011; Ponder & Long, 2013).  
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Age and gender are demographic factors that have an impact on the incidence and 
type of IBD. Relative to adult patients with IBD, there seems to be a higher incidence of 
CD than UC in pediatric patients, with a ratio of 2.8:1. Furthermore, there is a male to 
female ratio of 1.5:1 in children with CD, as compared to pediatric UC in which the ratio 
has been observed to be closer to 1:1. In contrast, there does not seem to be as clear an 
effect of gender on the incidence and prevalence of IBD in adult studies (Sauer & 
Kugathasan, 2010).  
 
Etiology of Inflammatory Bowel Disease 
IBD is thought to be a result of a confluence of genetic and environmental factors, 
though the exact relationship is unknown (Ponder & Long, 2013). Numerous genome 
wide association studies have identified more than 160 loci associated with susceptibility 
to IBD. Studies have shown that 5.7 to 15.5% of patients with UC have a first-degree 
relative with UC (Cioffi, 2015). Monozygotic twin studies have found a concordance rate 
of 50% for CD and 19% for UC (Ponder & Long, 2013). Another study reported a 16-
36% concordance rate in monozygotic twins (Benchimol et al., 2011). These findings 
clearly leave room for other factors to play a significant role in the development of IBD. 
There is now growing evidence to suggest that genetics play a more important role in 
early-onset pediatric IBD, partly because these patients have had less exposure to other 
potential environmental factors (Sauer & Kugathasan, 2010).  
Common environmental risk factors that have been studied in the pathogenesis of 
IBD include breast-feeding, smoking, diet, and antibiotic use (Loftus, 2004; Ponder & 
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Long, 2013). The effects of breast-feeding on the development of IBD are somewhat 
unclear. Most studies point to a protective role of breast-feeding against the development 
of IBD. However, it may be more important to look at the duration of breast-feeding. A 
more recent study found a protective effect only after a duration of at least three months 
(Ponder & Long, 2013; Cioffi, 2015). Smoking increases the risk of developing CD. 
However, there is an inverse relationship between active smoking and the risk of 
developing UC. In contrast, ex-smokers are 70% more likely to develop UC than people 
who have never smoked (Loftus, 2004; Ponder & Long, 2013). Studies implicating high 
dietary fat or sugar in the development of IBD have been inconclusive, though data 
suggest that diet does still seem to play some role (Loftus, 2004). There seems to be a 
clear connection between increased antibiotic exposure and a risk of developing IBD, 
especially when the antibiotics exposure occurred early in life. One retrospective study 
done in the UK compared the incidence of IBD in children, aged two and older, who 
either had been exposed to antibiotics or not. They found an 84% risk increase for 
developing IBD in those children who had been exposed to antibiotics. Furthermore, the 
risk decreased the older a child was and increased if a child took more than two courses 
of antibiotics. A Canadian study showed that if a child is exposed to antibiotics during the 
first year of life, the risk of developing IBD is increased by almost three-fold. However it 
remains unclear as to whether the effect of antibiotics is being mediated through direct 
effects on the intestinal microbiome or if antibiotic use is a marker for other predisposing 
factors directly related to the development of IBD (Ponder & Long, 2013).  
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Hypotheses related to risk factors associated with a Westernized life style have 
been proposed to explain the relationship between the environmental exposures and the 
development of IBD. The hygiene hypothesis suggests that the “cleaner” environments 
found in Western society are associated with higher prevalence of IBD, and that the 
greater prevalence of more harmful microbes in environments of less developed countries 
is associated with less IBD. One reason for this is because the interaction between the 
immune system and microbes fosters a regulated relationship between these two 
environments, allowing the immune system to learn to tolerate commensal bacteria while 
fighting harmful microbes. Therefore, when the immune system is exposed to fewer 
microbes, the immune system may develop improperly and as a result have an 
inappropriately severe response to commensal bacteria in the GI tract (Ponder & Long, 
2013). In contrast, the “cold-chain hypothesis” suggests that refrigeration of our food has 
selected the bacteria we ingest, thus contributing to the development of IBD (Benchimol 
et al., 2011). Specific bacteria, known as psychotropic bacteria, that exist and thrive at 
lower temperatures can be found in CD patients and may contribute to IBD pathogenesis 
(Hugot, et al., 2012). The exact effects of these factors on the development of IBD 
remain elusive and are likely to be better understood only when ongoing research better 
elucidates genetic interactions and their effects on the microbiome. 
In recent years, more attention has been paid to the intestinal microbiota and how 
alterations to it may lead to disease. The microbiota is acquired at birth but then 
undergoes many changes during the first few years of life. Figure 1 shows how the 
microbiota develops over time and what factors affect it. The microbiome encompasses 
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the genomic contents of the human microbiota, which is a community of microbes living 
within the human body. Newer studies have demonstrated that the interaction between 
the host immune system and the microbiota can be beneficial to the host, or can result in 
an apparent disequilibrium that can predispose toward the development of mucosal 
inflammation (Abraham & Cho, 2009). We know now that the microbiota plays an 
integral role in the development of the immune system, metabolism, and general 
homeostasis within the human body (Villanueva-Millán, Pérez-Matute, & Oteo, 2015).  
 
Figure 1: How The Intestinal Microbiome Develops. Figure was taken from 
(Villanueva-Millán, Pérez-Matute, & Oteo, 2015).  
 
When the microbiome is altered, or unbalanced, it is a known contributor to the 
development of disorders such as obesity, C. difficile infections, and IBD. Therefore, 
therapies with the intention of restoring the microbiome to a productive and balanced 
across individuals, the functional gene profiles are quite
similar [55], suggesting that knowledge of the metabolic
activity of microbiota might be more relevant than its
taxonomical composition. In fact, comprehension of the
role of human microbiota in health and disease requires
integration of taxonomical and metabolic features. In
order to achieve these goals, a combination of the afore-
mentioned metagenomic s quencing tools along with
metatranscriptomics, metaproteomics, and metabolo-
mics approaches to analyze RNA, protein, and small
metabolite pools from feces is needed [78]. Further-
more, the discrimination of bacterial metabolites from
metabolites that could be produced by the host is of
great interest in order not only to find out predictive
biomarkers for diseases characterized by alterations in
the gastrointestinal microbiota such as obesity, but also
to identify metabolites derived from nutrients to provide
benefits for gut health as will be described afterward
(polyphenols) [86].
Up to now, the main known functions of the micro-
biota can be broadly categorized into three groups:
metabolic (digestion), protective (protection against
pathogens), and trophic (control of epithelial cell prolif-
eration and differentiation) [39].
Metabolism
Gut microbiota is an important factor that affects energy
harvest from the diet and energy storage in the host.
Indeed, gut microbiota exerts a strong influ nce n host
lipid and cholesterol metabolism. In order to carry out
these metabolic functions, the enzymes from intestinal
microbiota such as glycoside hydrolases and polysac-
charide lyases have the ability to extract energy from
inaccessible nutrients, as these enzymes are able to
cleave glycoside linkages present in some plant poly-
saccharides and dietary fibers [8, 9]. As we have men-
tioned, the essential mechanism by which the intestinal
microbiota increases energy extraction from diet is
through the hydrolysis and subsequent fermentation of
the dietary polysaccharides. The indigestible polysac-
charides, as oligofructose (inulin), are metabolized by
colonic microbiota to oligosaccharides and monosac-
charides and then fermented to short chain fatty acids
Fig. 2 Factors involved in microbiota establishment from newborn to adult
M.J. Villanueva-Millán et al.
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state are being investigated as a way to treat the resulting disorders. These therapies 
include prebiotics, probiotics, and fecal transplants (Villanueva-Millán, Pérez-Matute, & 
Oteo, 2015).  
In the context of obesity, studies have shown that colonizing germ-free mice with 
the microbiome from obese mice makes the recipient mice obese. This highlights the 
effects of the microbiome on host metabolism and utilizing energy from food 
(Villanueva-Millán, Pérez-Matute, & Oteo, 2015). 
Of the many ways the microbiome can be altered, antibiotic use is the most 
common (Villanueva-Millán, Pérez-Matute, & Oteo, 2015). Antibiotics kill bacteria in 
the GI tract, therefore changing the composition of the microbiota. This becomes 
especially relevant in the case of C. difficile infections. The hallmark of a healthy 
microbiome is diversity. Studies show that patients who develop a C. difficile infection 
after antibiotic use have a less diverse microbiome than that of patients without an 
infection. Therefore the less diverse and unbalanced microbiota affects the host immune 
system’s ability to identify and fight harmful microbes (Monaghan, 2015).  
Additionally, because the microbiota is in constant contact with the immune 
system in the GI tract, changes to the microbiota can have an impact on how the immune 
system functions. In a healthy GI tract, the microbiota promotes an anti-inflammatory 
environment. When the microbiota becomes dysfunctional, the presence of harmful 
microbes can create a pro-inflammatory environment. This in turn causes further 
dysregulation of the microbiota perpetuating the evolution of inflammatory diseases like 
IBD (Maranduba et al., 2015).  
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Pathogenesis of Inflammatory Bowel Disease 
The most extensive subset of our immune system lies within the mucosa lining 
the gastrointestinal, pulmonary, and genitourinary tissues and is referred to as mucosal-
associated lymphoid tissue (MALT). This type of tissue interacts directly with the outside 
world and is therefore specialized in different parts of our body. For example, gut-
associated lymphoid tissue (GALT) is found in the GI tract (“Mucosa-Associated 
Lymphoid Tissue,” 2014). GALT represents the largest group of lymphoid tissues in our 
body, consisting of mesenteric lymph nodes, Peyer’s patches, and individual lymphocytes 
(Forchielli & Walker, 2005). These structures monitor the epithelial barrier and are 
responsible for differentiating between the commensal microbiome and invading 
pathogens. Dendritic cells (DCs) in particular are responsible for selectively responding 
to potential pathogens while remaining immune tolerant to native microbiota that 
populate the gut (Tezuka & Ohteki, 2010). 
In a healthy gut, immune homeostasis is dependent upon a bidirectional 
communication between the intestinal microbiota, the epithelium, and lymphoid tissue 
(Tezuka & Ohteki, 2010). In IBD, this balance can be disrupted through a pathological 
interaction between monitoring lymphoid cells and the microbiota. Additionally, when 
the epithelial layer is damaged or dysfunctional in some way, allowing excessive contact 
between the microbiota and lymphoid tissue, an inflammatory response can ensue. 
Defects in mucosal tight junctions between adjacent epithelial cells, as well as alteration 
in the mucus layer or secreted antimicrobial compounds, are examples of epithelial 
dysfunction that can predispose to inflammation. The ensuing inflammation can result in 
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ongoing epithelial injury, perpetuating the contact between the microbiota and lymphoid 
tissue and resulting in the chronic damage observed in the histologic findings from 
patients with IBD (Abraham & Cho, 2009).  
 
Diagnostic Techniques and Importance of Disease Differentiation  
It is difficult to differentiate between CD and UC based on clinical symptoms 
alone. Therefore, clinicians currently rely on a repertoire of biochemical tests, radiologic 
studies, and endoscopic evaluation with mucosal biopsies (Hendrickson et al., 2002). 
Radiologic tests, including MRI, CT scan and fluoroscopy, can be used to assess areas of 
the small intestine that cannot be reached using standard endoscopic procedures 
(Hendrickson et al., 2002). However, both CT scans and fluoroscopy expose the patient 
to radiation, which is more of a concern for pediatric patients, and MRI is very costly. In 
most cases, endoscopic and histologic studies can definitively differentiate between UC 
and CD.  Making the diagnosis of CD becomes easier if there is obvious inflammation of 
the small bowel, perianal disease is apparent, or if granulomas (collections of immune 
cells) are observed in the biopsy. An endoscopist can usually see some differences on the 
mucosal surface, such as deep ulcers and discontinuous inflammation, which would be 
indications of colonic CD. Visual signs of UC include confluent erythema, tissue 
granularity, and loss of vascular pattern on the mucosa. Even with these distinctions, 
there are patients in whom the clinical and histologic pictures exhibit features of both CD 
and UC. In these cases, clinicians categorize these patients as having “indeterminate 
colitis” (Bousvaros et al., 2007).  
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The cost and logistics inherent in the present paradigm for IBD diagnosis continue 
to motivate physicians to find more reliable ways of screening for and assessing patients 
with IBD (Bousvaros et al., 2007). In children with IBD, preventing a substantial delay in 
diagnosis is vital as untreated inflammation can result in an increased risk for growth and 
pubertal delay, and this can have a long lasting effect into adulthood (Sauer & 
Kugathasan, 2010). Patients with UC usually present with acute symptoms, such as 
bloody diarrhea, sooner than those with CD. In these cases, the more indolent 
presentation of CD can lead to delayed diagnosis (Hendrickson et al., 2002). 
Additionally, though endoscopy/colonoscopy is the “gold standard” for diagnosis of IBD, 
the procedure requires bowel preparation and anesthesia making this a costly and 
invasive experience for pediatric patients (Assche, 2011). This is yet another incentive to 
continue to develop better and more efficient ways of diagnosing and differentiating IBD 
in a pediatric population.  
 
Serologic and Fecal Biomarkers in IBD 
Physicians are now looking to serologic and fecal biomarkers to more efficiently 
and less invasively diagnose and differentiate between different forms of IBD. Serologic 
biomarkers can be useful in detecting non-specific inflammation (Abraham & Kane, 
2012). The most commonly used serologic biomarker used for the past 10-15 years is C-
reactive protein (CRP). CRP is an acute-phase protein that is produced by the liver. In 
response to an inflammatory condition, CRP is produced by hepatocytes and released into 
systemic circulation. The sensitivity for CRP for differentiating between UC and CD 
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ranges from 50-60%. Serum CRP levels reflect inflammation anywhere in the body and 
are therefore too non-specific to be used to diagnose or monitor IBD activity (Assche, 
2011; Cioffi, 2015). Another commonly used serologic biomarker for inflammation is 
erythrocyte sedimentation rate (ESR). Similar to CRP, an increased response in ESR is 
indicative of increased inflammation. ESR can provide insight into the changes in plasma 
protein composition during an inflammatory response (Cioffi, 2015).  
Fecal biomarkers allow physicians to measure proteins that originate from the GI 
tract, making them specific to GI inflammation. Existing data suggest that fecal 
biomarkers can help determine the need for further testing, assess disease activity, and 
track a patient’s response to treatment. For example, when a differential diagnosis 
includes IBD and irritable bowel syndrome (IBS), a functional non-inflammatory 
syndrome, measurement of fecal biomarkers helps determine if a patient is likely to 
benefit from endoscopic evaluation (Abraham & Kane, 2012). With respect to assessing 
disease activity in IBD, fecal biomarkers of inflammation, including fecal lactoferrin 
(FLA) and calprotectin, have been shown to correlate with disease activity with higher 
levels indicating greater disease activity in patients with IBD (Assche, 2011; Abraham & 
Kane, 2012). Eliminating or reducing the need for endoscopic evaluation to assess 
disease activity in patients with IBD is important especially in the case of pediatric 
patients (Assche, 2011). Though fecal biomarkers appear to be more specific for 
assessing intestinal inflammation than those measured in the serum, it is important to note 
that existing fecal biomarker levels do not differentiate autoimmune (IBD) from 
infectious causes of inflammation in the bowel (Assche, 2011; Abraham & Kane, 2012).  
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Serum ANCA and ASCA 
 Two serologic biomarkers that have been associated with IBD are anti-neutrophil 
cytoplasmic antibody (ANCA) and anti-Saccharomyces cerevisiae antibody (ASCA).  
ANCA levels have been shown to more closely correlate with UC than CD with rates of 
20-85% and 2-28%, respectively. In contrast, serum ASCA levels tend to correlate with 
CD more than UC with rates of 39-69% and 5-15%, respectively (Cioffi, 2015). 
However, the sensitivity of ASCA drops when the patient has purely colonic CD. In 
distinguishing IBD from non-inflammatory conditions with similar symptoms, such as 
IBS, ASCA has a sensitivity of 31-45% and a specificity of 90-100% for diagnosing IBD 
(Prideaux, et al., 2012). 
When these two biomarkers are used together, they yield a better diagnostic result 
than when used separately. Interestingly, one study showed that when reclassifying 
indeterminate colitis patients, a combined positive ASCA and negative ANCA predicted 
CD in 80% and a combined negative ASCA and positive ANCA predicted UC in 64% of 
these patients (Prideaux, et al., 2012).  
Stability of serologic ANCA and ASCA are of importance when used in the 
context of a dynamic disease such as IBD. Serum ASCA levels appear to be stable over 
time in patients with CD and across disease activity. ANCA appears to also be stable over 
time in both UC and CD across disease activity. As such, these serologic biomarkers 
cannot be used to assess the level of disease activity in patients with IBD (Prideaux, et 
al., 2012). In general, though serologic biomarkers such as ANCA and ASCA have been 
shown to be of some use in differentiating CD from UC, the results are not reliable 
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enough to replace the endoscopic, histologic, radiologic, and other clinical means of 
diagnosis.  
 
Fecal Lactoferrin  
FLA is a protein derived from neutrophils, cells that play a role in the innate 
immune response. FLA arising from intestinal neutrophils is stable and is not degraded 
by bacterial enzymes in the small or large intestine, thereby making it a reliable marker of 
inflammation in the intestine (Assche, 2011). FLA measurements are useful in 
differentiating patients with active IBD versus inactive IBD. Studies have shown FLA 
levels may correlate to UC activity, as opposed to CD activity (Abraham & Kane, 2012). 
Consequently, though FLA provides valuable information regarding the general diagnosis 
of IBD, further studies are necessary to define the best approach to using this fecal 
biomarker in the diagnosis and interval assessment of patients with IBD.   
 
Fecal ASCA 
ASCA is thought to be produced in mesenteric lymph node, though its exact 
purpose is unknown (Reese et al., 2006). Interestingly, studies have shown that the 
presence of ASCA does not seem to correlate with exposure to S. cerevisiae. Instead, the 
presence of these antibodies may not be indicative of increased permeability to microbes, 
but rather a decreased tolerance to microbes existing in our bodies (Prideaux, et al., 
2012). Like other serum antibodies, ASCA is also secreted into the stool and may be 
more informative as a fecal biomarker to both identify and assess disease activity in 
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patients with IBD. Almost no research has been done to date on the presence or utility of 
fecal ASCA in patients with IBD. One study was conducted comparing serologic and 
fecal ASCA against endoscopic findings in the context of assessing IBD patients who had 
surgical treatment for UC resulting the in the creation of an ileal pouch. One common 
complication of this surgery is developing Crohn-like disease (CDL) of the pouch. The 
researchers found that in determining the cause of pouch disease, fecal ASCA was more 
useful than serum ASCA in determining whether the cause was CDL or other pouch 
disorders (Tang et al., 2012).  
 
OBJECTIVES 
 Fecal biomarkers are an emerging area of research, and there are still many 
questions about which biomarkers are most accurate for use in assessing disease activity 
or differentiating between CD and UC. FLA and calprotectin have been shown to be 
useful in differentiating patients with inflammatory and those with non-inflammatory GI 
disorders. However they offer little insight into discerning the nature (infectious vs. 
inflammatory) or type (CD vs. UC) of inflammation. ASCA has been shown to have 
higher specificity for CD and we would like to extend this line of research. Specifically, 
we will evaluate:  
1. Whether fecal ASCA can differentiate between active and inactive CD 
in the same patient 
2. Whether fecal ASCA can differentiate between CD and UC 
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3. How information provided by fecal ASCA compares to that provided 
by FLA  
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METHODS 
Participants  
For this study, 47 pediatric patients (aged 0-18 years) with IBD were included in 
our analyses: 35 with CD, and 12 with UC. Participants were patients at Boston 
Children’s Hospital. To be eligible for our study, patients had to carry an established 
diagnosis of either CD or UC. Patients with HIV, Hepatitis B or C, or those who had 
undergone a total colectomy were excluded from our study. Furthermore, if patients were 
unable to provide a stool sample, they were also excluded. 
  
Recruitment  
We determined the eligibility of patients using PowerChart® to view patients’ 
medical history. PowerChart® is an electronic medical records database. Patients meeting 
the eligibility criteria were recruited in both inpatient and ambulatory settings. Approval 
was obtained from the Institutional Review Board. Once the eligibility of a patient was 
confirmed, we approached the patient to explain our study objectives and requirements 
for participation. We acquired consent from both the patient and a parent and assigned 
the patient a study ID number. Only the study ID number was used from this point 
forward to identify any data. For inpatients, we placed a collection cup in their inpatient 
bathroom and for outpatients, we gave the patient a stool collection kit to take home and 
mail back to us with a sample. When patients provided a stool sample, they were 
reimbursed $10 for their participation. Three to six months after the baseline stool sample 
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was provided, patients were contacted to provide a follow-up sample and were again 
reimbursed $10 if a follow-up stool sample was provided. 
 
Sample Processing and Testing 
Immediately after sample collection, the samples were stored at 20 °C for no 
longer than one week. The stool samples were subsequently transferred from the sample 
cups into 2 ml tubes. Stool samples were handled under a chemical hood and transferred 
using pipets or wooden spatulas. The 2 ml tubes were labeled and placed in a freezer at    
-80 °C for storage. 
Stool samples were batched and shipped overnight on dry ice to TECHLAB® 
(Blacksburg, VA) to be analyzed. To evaluate fecal ASCA, TECHLAB® used a 
commercially available assay, ASCA-CHEK. This enzyme-linked immunoassay uses 
antigens of ASCA to detect ASCA levels in feces. The ASCA-CHEK was run according 
to the TECHLAB® package insert (TECHLAB, Inc., 2008). To evaluate FLA, 
TECHLAB® used IBD-CHEK®, which is a qualitative ELISA. IBD-CHEK® was run 
according to the TECHLAB® package insert (TECHLAB, Inc., 2008). Both ASCA-
CHEK and IBD-CHEK are qualitative assays and the results are reported in terms of 
optical density (OD). Technicians at TECHLAB® were blinded to all patient information 
except the sample collection date. 
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Case Report Forms  
 A case report form (CRF) was completed for each patient who provided a 
baseline stool sample. If patients provided a follow-up sample at a later time point, the 
follow-up portion of the CRF was also completed. CRFs included relevant medical 
history of the patients, including information about diagnosis, medications, labs, and 
imaging studies (Figures 2-4). Additionally, information about the treatment received in 
the hospital at the time the stool sample was collected was also recorded in the CRFs. 
CRFs were completed using medical records from PowerChart®. 
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Figure 2: Disease Information Recorded on CRF. Section D includes the 
diagnosis, date of diagnosis based on diagnostic colonoscopy, the state of 
disease based on patient’s current symptoms, and general treatment goals if 
patient has active disease. Additionally previous relevant surgical treatments are 
recorded.  
 
 
 
 
SECTION D: DISEASE INFORMATION 
D1. Diagnosis:  CD……………………… 1 
    UC……………………… 2 
   Constipation………. 3 
D2. Date of Onset of Symptoms:  __ __ /__ __ /__ __ __ __ 
D3. Date of Diagnosis:                    __ __ /__ __ /__ __ __ __ 
D4. Activity:   Active……… 1 
(If 2, Skip to D6)  Inactive…… 2 
D5. Reason (if active): Increase dose of existing medications………. 1 
    Add new medications to control symptoms. 2 
    New testing to diagnose symptoms………….. 3 
    Missing...………………………………………………………  -9 
D6. Surgical Treatment:  Yes………..1 
(If 2, skip to E1)   No………….0 
D6a. Date:  __ __ /__ __ /__ __ __ __ 
D6b. Type:  Ileocecal Resection………………………………   1 
   Stricturplasty………………………………………..  2 
   Right Hemicolectomy……………………………  3 
   Left Hemicolectomy……………………………..  4 
   Colectomy and ileoanal pull through…..  5 
Other (specify_______________)………  6 
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Figure 3: Disease Classification on CRF. Section G includes specific 
information about the disease location and nature. This information is different 
depending on the diagnosis.  
 
 
 
 
SECTION G: MONTREAL CLASSIFICATION 
G1. Crohn Disease:  Yes………………..1  
     No………………….0 (if no, skip to G2) 
G1a. Age of Onset:  <16y…………...1 
     17-40y…………2 
G1b. Location:  Ileal………………_ 
   (1=yes, 0=no)          Colonic…………._ 
    Ileocolonic……_ 
    Upper GI…….._ 
G1c. Behavior:  Nonstricturing, Nonpenetrating……_ 
   (1=yes, 0=no)  Stricturing……………………………………._ 
    Penetrating………………………………….._ 
    Perianal disease modifier……………._ 
G2. Ulcerative Colitis:  Yes……………..1 
     No……………….0 (if no, skip to H1) 
 G2a. Extent:   Ulcerative proctitis…………1 
     Distal UC………………………2 
     Pancolitis……………………..3 
 G2b. Severity:  Remission…………………….1 
     Mild UC…………………………2 
     Moderate UC………………..3 
     Severe UC…………………….4 
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SECTION L: BASELINE BLOOD WORK 
  
CBC  
L1. WBC              _ _ . _ _  K cells/uL 
L2. HCT              _ _ _ . _ mg/dL 
L3. PLT                _ _ _ _ mg/dL 
L4. Neutrophils                      _ _ % 
L5. Lymphs                      _ _ % 
L6. Eos                      _ _ % 
L7. Monos                      _ _ % 
  
Chemistry  
L8.   Albumin                    _ . _ g/dL 
L9.   SED Rate                      _ _ mm/hr 
L10. ASCA                 _ _ . _ eu/mL 
L11. ANCA              _ _ _ . _ eu/mL 
L12. Amylase                   _ _ _ unit/L 
L13. ALT                      _ _ unit/L 
L14. Bilirubin (Tot)                    _ . _ mg/dL 
L15. Alkaline 
        Phosphatase 
                  _ _ _ unit/L 
L16. CRP                 _ . _ _ mg/dL 
 
SECTION M: BASELINE LEVELS 
  
M1. IBD- CHEK™ Fecal Lactoferrin 
(OD450/620) 
_ . _ _ _ 
M2. IBD- CHEK™ Interpretation Positive………….1 
Negative………..0 
M3. IBD-SCAN™ Fecal Lactoferrin 
(µg/mL) 
_ _ _ . _ µg/mL 
M4. IBD-SCAN™ Interpretation Positive………….1 
Negative………..0 
M5. Fecal ASCA-CHEK™ (OD450/620) _ . _ _ _ 
M6. Fecal ASCA-CHEK™ Titer _ _ _ _ 
M7. Fecal ASCA-CHEK™ Interpretation Positive………….1 
Negative………..0 
M8. Serum ASCA-CHEK™ (OD450/620) _ . _ _ _ 
M9. Serum ASCA-CHEK™ Titer _ _ _ _ 
M10. Serum ASCA-CHEK™ Interpretation Positive………….1 
Negative………..0 
 
Figure 4: Serum and Fecal Lab Values on Day of Sample Collection. 
Sections L and M include serum and fecal lab values, respectively, on or around 
the same day. These values can be used to compare different types of 
inflammatory markers such as the serologic biomarker CRP and fecal biomarker 
ASCA.  
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RESULTS 
Patient Population 
Our analyses included 47 patients (35 with CD and 12 with UC) who provided 
both a baseline and follow-up sample. Active disease was defined as patients 
experiencing increased clinical symptoms, including diarrhea and abdominal pain. To 
address this, clinicians typically added a medication, changed the dose of an existing 
medication, or ordered diagnostic studies to better elucidate the nature of a patient’s 
increased symptoms. During an inactive disease state, patients were in clinical remission 
and were not experiencing clinical symptoms of their disease. Analyzing paired samples 
allowed us to evaluate fecal biomarker levels in both active and inactive disease within 
the same patient. We used non-parametric tests given our relatively small sample sizes.  
 
Effect of Disease Activity on ASCA Levels 
We first conducted a related-samples Wilcoxon signed rank test (“Wilcoxon 
Signed Rank Test,” 2013) comparing the fecal ASCA levels in active versus inactive CD 
and UC separately. We found that fecal ASCA levels were significantly higher (p = .001) 
in CD patients with active disease than in those with inactive disease (Figure 5).  In 
contrast, in patients with UC, fecal ASCA levels were not significantly different (p = 
.859) in active and inactive disease states (Figure 6).  
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Figure 5: Effect of Crohn Disease Activity on ASCA Levels. This graph 
depicts ASCA levels on the y-axis (OD, optical density) and the CD activity state 
on the x-axis. ASCA levels are significantly higher in patients when their disease 
is active than when it is inactive. This analysis included 35 CD patients’ paired 
samples. (**p <.01) 
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Figure 6: Effect of Ulcerative Colitis Activity on ASCA Levels. This graph 
depicts ASCA levels in on the y-axis (OD, optical density) and the UC activity 
state on the x-axis.  ASCA levels are not significantly different in active vs. 
inactive disease. This analysis included 12 UC patients’ paired samples. (=p > 
.05)  
 
We conducted an independent-samples Mann-Whitney U test (“Mann-Whitney U 
Test,” 2013) to compare ASCA levels in patients with active CD to those observed in 
patients with active UC. We repeated this test to compare ASCA levels in patients with 
inactive CD and inactive UC. We found that ASCA levels measured in patients with 
active CD are significantly higher (p = .000) than those observed in patients with active 
UC. Similarly, ASCA levels in patients with inactive CD are significantly higher (p = 
.024) than in inactive UC. This comparison shows that not only does ASCA reflect 
disease activity, but may also help to differentiate patients with CD from those with  UC 
(Figure 7).  
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Figure 7: ASCA Levels Differentiate Between CD and UC. This graph depicts 
ASCA levels on the y-axis (OD, optical density) and both the disease and activity 
state on the x-axis. Here we compared active disease and inactive disease 
across CD and UC. ASCA levels are significantly higher in CD regardless of 
disease activity. (**p <.01, *p <.05) 
 
Effect of Disease Activity on FLA Levels 
We conducted a related-samples Wilcoxon signed rank test comparing the FLA 
levels in patients with active versus inactive CD and UC separately. We found that in 
patients with CD, FLA levels were significantly higher (p = .021) when their disease was 
active than when it was inactive (Figure 8). In contrast, in patients with UC, FLA levels 
did not discriminate between patients with active and inactive disease (p = .060, Figure 
9).  
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Figure 8: Effect of Crohn Disease Activity on FLA Levels. This graph depicts 
FLA levels on the y-axis (OD, optical density) and CD activity state on the x-axis. 
FLA levels are significantly higher in active disease than in inactive disease 
within the same patient. This analysis included 35 CD patients’ paired samples. 
(*p < .05)  
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Figure 9: Effect of Ulcerative Colitis Disease Activity on FLA Levels. This 
graph depicts FLA levels on the y-axis (OD, optical density) and UC activity state 
on the x-axis. FLA levels are not significantly different in active disease and 
inactive disease in patients with UC. This analysis included 12 UC patients’ 
paired samples. (=p >.05)  
 
 
We conducted an independent-samples Mann-Whitney U test to compare FLA 
levels in active CD to active UC, then inactive CD to inactive UC. We found FLA levels 
in patients with active CD were not significantly different (p = .643) from those measured 
in patients with active UC. Similarly, FLA levels in patients with inactive CD were not 
significantly different (p = .065) those measured in patients with inactive UC. This data 
suggests that FLA is not a specific marker of disease activity and cannot be used to 
differentiate between patients with CD and those with UC (Figure 10).  
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Figure 10: FLA Levels Cannot Differentiate Between CD and UC. This graph 
depicts FLA levels on the y-axis (OD, optical density) and both disease and 
activity state on the x-axis. Here we compared active disease to inactive disease 
across CD and UC. FLA levels do not differ between CD and UC depending on 
disease activity. (=p > .05) 
 
Overall Change in Fecal Biomarker Levels  
To illustrate the overall decrease in fecal biomarker levels between the active and 
inactive disease states, we calculated the change (active – inactive) in ASCA and FLA 
levels in patients with CD and UC. We then compared the delta values of ASCA and 
FLA in CD and UC. There was a significantly greater (p = .022) decrease in ASCA levels 
in patients with CD than in those with UC (Figure 11). In contrast, there was no 
significant difference (p = .223) in the change in FLA between patients with CD or UC 
(Figure 12).  
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Figure 11: Overall Change in ASCA Levels in CD and UC. This graph depicts 
the change in ASCA levels on the y-axis (OD, optical density) and disease on the 
x-axis. The decrease in ASCA, from active disease to inactive disease, in CD 
was significantly larger than the decrease in UC. (*p < .05)  
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Figure 12: Overall Change in FLA Levels in CD and UC. This graph depicts 
the change in FLA levels on the y-axis (OD, optical density) and disease on the 
x-axis. The decrease in FLA, from active disease to inactive disease, did not 
differ depending on the diagnosis. (=p > .05)  
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DISCUSSION 
The incidence of IBD is increasing worldwide, and researchers and physicians are 
highly motivated to continue to improve the diagnostic and treatment of this disease. 
Current standards of diagnosis, including endoscopic exam, are costly and invasive, 
especially for pediatric patients. Biomarkers of inflammation have been studied to help 
evaluate IBD. Serologic biomarkers, such as CRP and ESR, reliably indicate 
inflammation, but are non-specific to disease state within the GI tract (Assche, 2011; 
Abraham & Kane, 2012). Other serologic biomarkers such as serum ANCA and serum 
ASCA are slightly better at differentiating between CD and UC, with ANCA being more 
specific to UC and ASCA being more specific to CD (Prideaux et al., 2012; Cioffi, 
2015). However, there are no serologic biomarkers that have been studied to date that 
have been shown to reliably differentiate between CD and UC. As such, fecal biomarkers 
may provide a more specific picture of inflammation in the GI tract. Fecal biomarkers, 
such as FLA, have been shown to provide some valuable insight into the differentiation 
of IBD (Abraham & Kane, 2012). More research examining fecal biomarkers in patients 
with IBD may be able to contribute to a less invasive and costly clinical experience for 
patients and families.  
To date, little research has been done to examine the utility of fecal ASCA in the 
diagnosis of IBD. Serum ASCA measurements have been studied, and existing data 
suggest that levels of serum ASCA are stable over time and tell little about the dynamic 
nature of IBD (Prideaux et al., 2012). In one study comparing serum ASCA against fecal 
ASCA in patients with pouch disease, researchers concluded that fecal ASCA was better 
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than serum ASCA in identifying CDL in a pouch, versus other pouch disorders (Tang et 
al., 2012).  
Our study was the first study to assess fecal ASCA as a dynamic biomarker that 
can reflect disease activity and differentiate between the two forms of IBD (CD and UC). 
Additionally, we designed this study as a prospective study with the intention of 
assessing the change in ASCA levels within each patient. If fecal ASCA levels are higher 
during a state of active disease than during a state of inactive disease within the same 
patient, we can draw more robust conclusions about the utility of fecal ASCA as a 
dynamic marker of disease. We did not rely on absolute levels, which may vary 
dramatically from person to person, or use a cross-sectional study design in order to 
reduce the variance in our results.  
In this study, we demonstrated that fecal ASCA levels measured in the same 
patients over time can help to distinguish between active and inactive disease states, and 
display distinct dynamic ranges in patients with CD vs. those with UC. Higher ASCA 
levels were more likely to be observed in patients with active CD. Higher ASCA levels 
were observed in patients with CD regardless of whether the patient is having active 
symptoms or not. We did not observe the same dynamic relationships when we studied 
FLA levels in patients in active and inactive disease states. While FLA levels did 
distinguish between CD patients with active and inactive disease, there was no difference 
in FLA levels in patients with active CD or UC. One caveat to keep in mind is that 12 
patients were included in the analyses for UC while 35 patients were analyzed with CD. 
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This difference in number may have some effect on these comparisons, and ideally we 
would have the same number of patients in each group.  
Finding a fecal biomarker that demonstrates specificity for CD or UC would be a 
very valuable and novel tool. A tool such as this could help to decrease the need for 
invasive procedures to stage and assess IBD. In the case of a new diagnosis, an ASCA 
level above a clinically relevant threshold could expedite the diagnostic process, perhaps 
prompting a more expedient referral for endoscopic evaluation, thereby avoiding a 
delayed diagnosis of CD. In addition, in patients with an existing diagnosis of CD, 
physicians may only need to rely on fecal ASCA levels to assess patients’ response to 
therapy, since, given that in this small study, FLA provided little additional information. 
In summary, measuring fecal ASCA levels in patients with CD may help physicians 
assess disease state and a potential need to change or escalate medical.  
  
Future Directions  
Given our new insight into the utility of fecal ASCA, we are now looking to new 
questions fecal ASCA may help us answer. Many patients, especially pediatric patients, 
are diagnosed with indeterminate colitis initially, which can neither be defined as CD nor 
UC (Bousvaros et al., 2007). Looking at changes in fecal ASCA levels in these patients 
may predict which diagnosis is more likely. In patients with indeterminate colitis, a high 
ASCA level pointing to CD may help physicians tailor treatment at an earlier stage and 
avoid trialing drugs that have varying effects in UC and CD. Any way to save time in the 
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diagnostic and treatment process is less time a patient is suffering symptoms as well as 
less time secondary effects such as malabsorption and growth delay have to take effect.  
Additionally, evaluating ASCA levels during treatment for IBD may help 
physicians track patients’ response to new treatment and sustained response to treatments. 
For example, evaluating ASCA levels in both CD and UC patients undergoing treatment 
with Remicade®, a biologic immunomodulator (“Official Website for REMICADE®,” 
2014), could shed light on how effective this drug is in one disease over another.  More 
biologic drugs are being created now with indications for IBD and other inflammatory 
diseases. Many of these drugs have substantial cost, require invasive administration, and 
have potential significant side effects. Having a method of testing the efficacy of a drug 
sooner than observation alone could potentially avoid unwanted drug reactions, wasted 
time and money, and more timely resolution of symptoms.  
Our findings provide a foundation upon which larger studies looking at the utility 
of fecal ASCA can be based. More information on fecal ASCA, as well as other fecal 
biomarkers, will continue to provide valuable insight into the differences between CD 
and UC, as well as more tools with which to improve patient care and outcomes.  
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